Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Authors:
- Keyur PatelKPKeyur Patel
- Sumeet K. AsraniSASumeet K. Asrani
- Maria Isabel FielMFMaria Isabel Fiel
- Deborah LevineDLDeborah Levine
- Andres Duarte-RojoADAndres Duarte-Rojo
- Jonathan A. DranoffJDJonathan A. Dranoff
- Tarek NayfehTNTarek Nayfeh
- Bashar HasanBHBashar Hasan
- Tamar H. TaddeiTTTamar H. Taddei
- Yahya AlsawafYAYahya Alsawaf
- Samer SaadiSSSamer Saadi
Top Cited Papers
- 15 March 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , 358-379
Abstract
Background and Aims: Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4), as compared to biopsy in chronic liver disease. Approach and Results: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022. Two independent reviewers selected 286 studies with 103,162 patients. The most frequently identified studies included the simple aspartate aminotransferase-to-platelet ratio index and fibrosis (FIB)-4 markers (with low-to-moderate risk of bias) in HBV and HCV, HIV-HCV/HBV coinfection, and NAFLD. Positive (LR+) and negative (LR−) likelihood ratios across direct and indirect biomarker tests for HCV and HBV for F2-4, F3-4, or F4 were 1.66–6.25 and 0.23–0.80, 1.89–5.24 and 0.12–0.64, and 1.32–7.15 and 0.15–0.86, respectively; LR+ and LR− for NAFLD F2-4, F3-4, and F4 were 2.65–3.37 and 0.37–0.39, 2.25–6.76 and 0.07–0.87, and 3.90 and 0.15, respectively. Overall, the proportional odds ratio indicated FIB-4 1.5 for F3-4 and F4. There was limited data for combined tests. Conclusions: Blood-based biomarkers are associated with small-to-moderate change in pretest probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV coinfection, and NAFLD, with limited comparative or combination studies for other chronic liver diseases.Keywords
This publication has 260 references indexed in Scilit:
- Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 DiabetesHepatology Communications, 2020
- Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesHepatology, 2019
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy StudiesJAMA, 2018
- Aspartate transaminase to platelet ratio index and gamma‐glutamyl transpeptidase‐to‐platelet ratio outweigh fibrosis index based on four factors and red cell distribution width‐platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis BJournal of Clinical Laboratory Analysis, 2017
- Noninvasive Diagnosis of Liver Fibrosis and Cirrhosis in Chronic Hepatitis C PatientsJournal of Clinical Laboratory Analysis, 2013
- SAFE biopsyHepatology, 2009
- FIB-4Hepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A novel panel of blood markers to assess the degree of liver fibrosis†Hepatology, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005